Joaquin Duato: Thank you for the question. And it’s difficult for us to comment on some of your topics there. There’s no approved biosimilars at this time, and we are going to continue to monitor the situation. As we have commented, we expect the erosion curve of STELARA to be likely steeper than that of REMICADE, given the evolution of the biosimilar market and the fact that STELARA is a self-administered product, as well as potentially to your point, potentially interchangeability in the label. So, that’s how we see the STELARA loss of exclusivity. In 2023, when we think about the STELARA in the U.S., we see the sales of STELARA flat to declining, obviously, given the price pressures. That will be offset also by continuous volume growth that we see in STELARA.
So, that’s the perspective that we have for STELARA in 2023. Overall, we have a very strong immunology franchise. I commented on TREMFYA before, the continuous progression in psoriasis, psoriatic arthritis, the readout of our ulcerative colitis and Crohn’s disease studies, which is exciting. And also, in 2023, we may have some data from our Phase 2 study of our oral IL-23, which we think it’s a very exciting underappreciated opportunity in our pipeline, too.
Operator: Next question today is coming from Chris Shibutani from Goldman Sachs.
Chris Shibutani: The multiple myeloma franchise, obviously, very central to your objective for 2025. Between the CAR-T sort of gradual launch that you have based upon supply and the bispecifics, can you talk about what that interplay has been since the approval and launch, and what you’re expecting through the year in 2023? Thank you.
Joaquin Duato: As far as the demand for CARVYKTI, we see very strong demand for CARVYKTI and also for TECVAYLI. There’s a significant need for new therapies in this relapsed/refractory patient population. So, the demand for the products, the physicians and patient adoption has been really strong. So, that is really encouraging and pertains the unmet medical need for these types of patients. With CARVYKTI, we continue to scale our production capacity and expand our network of providers, and we are doing that in a phased approach. With TECVAYLI, we are off to a successful start and the early indications for this of the self-option are very, very positive, too, connected with the high unmet medical need that we see there. Moving into 2023, key elements of that would be, from a data perspective, the reading CARTITUDE-4, which would give us the opportunity to move CARVYKTI into earlier lines of therapy.
Also the filing of Talquetamab, which will give us another line of therapy, because some of the studies of Talquetamab are done in patients who have failed BCMA, either cell therapy or bispecifics, and the continuous data that we’ll continue to provide to guide how to use this incredible portfolio in multiple myeloma.
Jessica Moore: Sorry. Sorry, Kevin. We have time for one last question.
Operator: Perfect. Our final question today is coming from Louise Chen from Cantor Fitzgerald.
Louise Chen: I wanted to ask you about the timing of data readouts first half or second half and your expectations for a few products. First one is nipocalimab and rheumatoid arthritis. And then, your oral IL-23 I saw that a trial was finished and what your next steps are here and when you might have some data? And then lastly, just on your RYBREVANT and lazertinib, are you still expecting a potential interim readout for lung cancer here? Thank you.
